8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________________

FORM 8-K

_________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 30, 2023

_________________________________________________________________

C4 THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

_________________________________________________________________

Registrant’s Telephone Number, Including Area Code: (617) 231-0700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors: Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 30, 2023, Adam S. Crystal, M.D., Ph.D., informed us of his intent to resign from his position as the Chief Medical Officer of C4 Therapeutics, Inc. (the “Company” or “us”), effective as of February 24, 2023, to pursue an opportunity as a head of research and development. After February 24, 2023, Dr. Crystal will cease to be employed by the Company and cease to serve in the role of Chief Medical Officer.

In order to provide for the orderly transition of his responsibilities, Dr. Crystal has agreed to provide transitional services after his departure on an as needed basis until September 1, 2023 under the terms of a consulting agreement.

Item 7.01 Regulation FD Disclosure

In connection with Dr. Crystal’s upcoming departure, the Company has engaged Hagop Youssoufian, M.D. as a clinical development consultant and, upon Dr. Crystal’s departure, as the Company’s interim Chief Medical Officer. In this role, Dr. Youssoufian will provide advisory and other services to support the Company’s operations while the Company completes an ongoing search for a permanent Chief Medical Officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.